GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » EPS without NRI

MDXXF (Pharmala Biotech Holdings) EPS without NRI : $-0.00 (TTM As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings EPS without NRI?

Pharmala Biotech Holdings's earnings per share without non-recurring items for the three months ended in Nov. 2024 was $0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Pharmala Biotech Holdings's EPS without NRI or its related term are showing as below:

MDXXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 30.7   Med: 30.7   Max: 30.7
Current: 30.7

During the past 4 years, Pharmala Biotech Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.70% per year. The lowest was 30.70% per year. And the median was 30.70% per year.

MDXXF's 3-Year EPS without NRI Growth Rate is ranked better than
74.29% of 1233 companies
in the Biotechnology industry
Industry Median: 10.2 vs MDXXF: 30.70

Pharmala Biotech Holdings's EPS (Diluted) for the three months ended in Nov. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00.

Pharmala Biotech Holdings's EPS (Basic) for the three months ended in Nov. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00.


Pharmala Biotech Holdings EPS without NRI Historical Data

The historical data trend for Pharmala Biotech Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings EPS without NRI Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
EPS without NRI
-0.02 -0.01 -0.01 -0.01

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmala Biotech Holdings's EPS without NRI

For the Biotechnology subindustry, Pharmala Biotech Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's PE Ratio without NRI falls into.


;
;

Pharmala Biotech Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings  (OTCPK:MDXXF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pharmala Biotech Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.